Kātao was founded with the primary aim of providing investors with access to Israel's best early-stage bio-convergence investment opportunities. We identify the right entrepreneurs and technologies to achieve the highest returns while helping humanity.

Kātao enables entrepreneurs’ to transition from research to market readiness through hands-on management and early-stage cooperation with prominent partners.

The Kātao team brings extensive experience in managing and growing early-stage companies, helping the portfolio companies to achieve a successful outcome.